Stocks Rally, Dow Rises 700 Points On News Of Gilead’s Possible Coronavirus TreatmentForbes • 04/17/20
Whether or Not Gilead Sciences Produces a Successful COVID-19 Therapeutic, It's a BargainThe Motley Fool • 04/17/20
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks OverdoneBenzinga • 04/17/20
Gilead Stock Jumps 8% After Coronavirus Drug Remdesivir Shows ‘Rapid Recoveries’ In Clinical TrialsForbes • 04/17/20
Gilead's Remdesivir Shows Promise Against COVID-19 in Sneak Peek at Clinical Trial DataThe Motley Fool • 04/17/20
Stocks Rally, Dow Jumps 600 Points On News Of Gilead’s Possible Coronavirus TreatmentForbes • 04/17/20
Stocks Rally, Dow Jumps Nearly 700 Points On News Of Gilead’s Possible Coronavirus TreatmentForbes • 04/17/20
Former FDA Commissioner Says Gilead's Remdesivir Could Have Enough Data For Emergency Use AuthorizationBenzinga • 04/17/20
Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts saysCNBC • 04/17/20
Stock Futures Surge as Gilead’s Remdesivir Could Be COVID-19 Top Treatment Candidate24/7 Wall Street • 04/16/20